GlassScriptPhysician profile
Kelly C Chamberlain
NPI 1891971552
$4,898.07
in general payments reported to CMS, 2019-2025
23 companies · $4,315 in 2025
The $4,315 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $19.13 · 2021: $199 · 2022: $37.51 · 2023: $14.44 · 2024: $194 · 2025: $4,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,254 · Food and Beverage: $681 · Travel and Lodging: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,254.14 |
| Food and Beverage | $680.69 |
| Travel and Lodging | $588.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,921.33 | 2025 | |
| Abbvie INC. | $142.44 | 2019-2024 | |
| Astellas Pharma US INC | $134.49 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $120.50 | 2019-2025 | |
| Hologic Sales and Service, LLC | $99.49 | 2021-2025 | Aptima, Thinprep 2000 Processor, Acessa Provu System |
| Organon LLC | $80.72 | 2022-2025 | Jada System, Nexplanon |
| Pfizer INC. | $48.79 | 2025 | |
| Therapeuticsmd, INC. | $44.65 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $35.21 | 2025 | Myfembree, Gemtesa |
| Exact Sciences Corporation | $33.29 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lupin INC. | $31.00 | 2019 | |
| Biogen, INC. | $24.60 | 2025 | Zurzuvae |
| Meditrina | $22.64 | 2025 | |
| Globus Medical, INC. | $21.57 | 2024 | Excelsius3d Imaging System |
| Sage Therapeutics, LLC | $21.55 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $19.84 | 2025 | Paragard T 380a |
| Duchesnay USA Incorporated | $18.76 | 2019 | |
| Evofem Biosciences, INC. | $18.74 | 2021 | |
| Merck Sharp & Dohme LLC | $16.36 | 2019 | |
| Mayne Pharma Commercial LLC | $14.30 | 2025 | |
| Myovant Sciences INC. | $13.97 | 2021 | |
| Coloplast Corp | $13.83 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.